Short answer
CorMedix Inc. (CRMD) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $127M (up 226.1% year over year) with net income of $39M.
Q1 2026 key financials · XBRL
- Revenue
- $127M
- +226.1% YoY
- Net income
- $39M
- +87.0% YoY
- Operating margin
- 50.0%
- Gross margin
- 82.5%
- EPS (diluted)
- $0.43
- +43.3% YoY
Source: XBRL data from the CorMedix Inc. (CRMD) Q1 2026 10-Q on SEC EDGAR. USD.
CorMedix Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $127.4M, up 226% YoY from $39.1M, including Melinta Portfolio product sales of $24.4M
- Gross margin 82.5% vs 95.9% YoY, with gross profit $105.1M versus $37.5M
- DefenCath best-performing product, sales $97.5M versus $39.1M YoY
- Cash and short-term investments $178.1M versus $148.5M at December 31, 2025
- Operating cash flow $42.4M versus $19.7M YoY, with $12.1M financing cash use from repurchases and tax payments
- Outlook: DefenCath net pricing expected to decline in second-half 2026 as TDAPA transitions; tariffs may pressure gross margins
Risk Factors
- No Risk Factors section provided; changes from the most recent 10-K cannot be assessed
- Share-repurchase liquidity risk: $1.589 million shares repurchased during February–March 2026
- Capital-allocation risk: $63.908 million remaining under the $75 million repurchase authorization
- Executive-retention risk: amended agreements provide 12-month salary continuation after qualifying termination
- Change-in-control risk: qualifying termination within 24 months triggers 125% salary-plus-bonus severance over 15 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CorMedix Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.